Patient Characteristics, Disease Burden, Treatment Patterns and Outcomes in Patients with Acromegaly

Real-World Evidence from the Malaysian Acromegaly Registry

Authors

Keywords:

acromegaly, malaysian registry, healthcare resource utilization, treatment outcomes

Abstract

Objective. This study is intended to report the demographic features of patients with acromegaly the disease burden, treatment patterns as well as the corresponding treatment outcome in Malaysia.

Methodology. Data from the Malaysian Acromegaly registry was retrospectively collected and included patients diagnosed with acromegaly from 1970 onwards. Data collected included patient demographics, clinical sign and symptoms as well as clinical manifestations of acromegaly, biochemical results and imaging information. Information regarding treatment modality and therapeutic outcome of different modalities of treatment were also collected.

Results. Data from the registry was collected from 2013-2016 and included 140 patients with acromegaly from 12 participating hospitals. Median disease duration was 5.5 years (range 1.0 – 41.0 years). Most patients had macroadenoma (67%) while a minority were diagnosed with microadenoma (15%). Hypertension (49.3%), diabetes (37.1%) and hypopituitarism (27.9%) were the most common co-morbidities for patients with acromegaly. Majority of patients had first line surgical intervention (65.9%) while 20.7% had first line medical treatment, mainly with dopamine agonist (18.5%). Most patients had inadequate disease control after first line treatment regardless of treatment modality (79.4%).

Conclusion. This registry study provides the epidemiology data of patients with acromegaly in Malaysia and serves as an initial step for further population-based studies.

Downloads

Download data is not yet available.

Author Biographies

Mohamed Badrulnizam Long Bidin, Hospital Kuala Lumpur, Malaysia

Consultant Endocrinologist

Florence Hui Sieng Tan, Hospital Umum Sarawak, Malayisa

Consultant Endocrinologist

Nor Azizah Aziz, Hospital Pulsu Pinang, Malaysia

Consultant Endocrinologist

Norhaliza Mohd Ali, Hospital Sultanah Aminah Johor Bahru, Malaysia

Consultant Endocrinologist

Nor Azmi Kamaruddin, Hospital Canselor Universiti Malaya, Malaysia

Consultant Endocrinologist

Shireene Vethakkan, Pusat Perubatan Universiti Malaya, Malaysia

Consultant Endocrinologist

Abdul Mueed Khan, Novartis Corporation (M) Sdn Bhd, Malaysia

Medical Manager

Balraj Sethi, Novartis Corporation (M) Sdn Bhd, Malaysia

Medical Director

Zanariah Hussein, Hospital Putrajaya, Malaysia

Consultant Endocrinologist

References

Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189-3202

Burton T, Le Nestour E, Neary M, Ludlam W. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. 2016;19:262-267.

Broder M, Chang E, Cherepanov D, Neary M, Ludlam W. Incidence and prevalence of acromegaly in the United States: a claims-based analysis. Endocr Pract. 2016;22:1327-1335.

Dal J, Feldt-Rasmussen U, Andersen M, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016;175:181-190.

Gatto F, Trifirò G, Lapi F, et al. Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. Endocrinology. 2018. doi: 10.1007/s12020-018-1630-4. In.

Kwon O, Song YD, Seong YK, Lee EJ; for the Rare Disease Study Group, Science and Research Committee, Korean Endocrine Society. Nationwide survey of acromegaly in South Korea. Clin Endocrinol (Oxf). 2013;78:577-585. In.

Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40:268-332.

Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019;5:20.

Tirosh A, Shimon I. Complications of acromegaly: thyroid and colon. Pituitary. 2017;20:70-5.

Pivonello R, Auriemma RS, Grasso LF, et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary. 2017;20:46-62.

Dineen R, Stewart PM, Sherlock M. Acromegaly. QJM 2017;110:411–20.

Nabarro JD. Acromegaly. Clin Endocrinol (Oxf) 1987;26:481–512.

Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994;73:233–40.

Chanson P and Salenave S. Acromegaly. Orphanet J Rare Dis. 2008;3:17

Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020;182:523-31.

Kreitschmann-Andermahr I, Buchfelder M, Kleist B, Kohlmann, et al. Predictors of quality of life in 165 patients with acromegaly: results from a single-center study. Endocr Pract. 2017;23:79-88.

Hussein Z, Bidin M, Alias A et al. Malaysian consensus statement for the diagnosis and management of acromegaly. J ASEAN Fed Endocr Soc 2019;34(1):8-14.

Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-51.

Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Endocr Pract. 2011;17(Suppl 4):1-44.

Matsubayashi K, Kawakami K. Prevalence, incidences, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database. Endocr J. 2020;67(10):997-1006.

Yun SJ, Lee, JK, Park SY, Chin SO. Descriptive Epidemiology and Survival Analysis of Acromegaly in Korea. J Korean Med Sci. 2021;36(23):e159.

Guo X, Wang K, Yu S, Gao L, et al. Patient Characteristics, Diagnostic Delays, Treatment Patterns, Treatment Outcomes, Comorbidities, and Treatment Costs of Acromegaly in China: A Nationwide Study. Front Endocrinol (Lausanne). 2020;11:610519.

Tseng F, Huang T, Lin J, Chen S, et al. A registry of acromegaly patients and one year following up in Taiwan. J Formos Med Assoc. 2019;118(10):1430-1437.

van der Lely AJ, Hutson RK, Trainer PJ, et al.. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754-9

Hannon MJ, Barkan AL, Drake WM. The role of radiotherapy in acromegaly. Neuroendocrinology. 2016;103:42-49.

Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14:552-61.

Frara S, Maffezzoni F, Mazziotti G, Giustina A. The modern criteria for medical management of acromegaly. Prog Mol Biol Transl Sci. 2016;138:63–83.

Bolanowski M, Adnan Z, Doknic M et al. Acromegaly: Clinical care in Central and Eastern Europe, Israel and Kazakhstan. Front Endocrinol (Lausanne). 2022;13:816426.

Christofides E. Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient Prefer Adherence. 2016;10:1217-1225.

Published

2022-11-16

How to Cite

Long Bidin, M. B., Tan, F. H. S., Aziz, N. A., Mohd Ali, N. ., Kamaruddin, N. A., Vethakkan, S., Khan, A. M., Sethi, B., & Hussein, Z. (2022). Patient Characteristics, Disease Burden, Treatment Patterns and Outcomes in Patients with Acromegaly: Real-World Evidence from the Malaysian Acromegaly Registry. Journal of the ASEAN Federation of Endocrine Societies. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/2465

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 3 4 5 > >>